Effect of Zinc Suplementation on Serum Hemosystein Level in Hemodialysis Patients

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01101217

Enrollment

100

Registered

2010-04-09

Start date

2009-02-28

Completion date

2009-09-30

Last updated

2010-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End Stage Renal Failure

Keywords

hemocystein zinc renal failure

Brief summary

The purpose of this study is to study the effect of zinc supplementation in end stage renal failure on hemocystein level.

Detailed description

hemocystein increased in end stage renal failure and zinc involved in hemocystein metabolism thus zinc supplementation may be effective on hemocystein level.

Interventions

DRUGZinc Supplement

in 50 patients zinc sulfate 220 mg per day orally for 6 weeks

DRUGplacebo

placebo daily for 6 weeks

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* hemodialysis for 3 months * older than 18 years old * serum level of zinc less than 72.6 microgram/ l in men and less than 70 microgram/ l in female

Exclusion criteria

* acute renal failre * malabsorption * history of steroid or cytotoxic consumption

Design outcomes

Primary

Measure	Time frame
decreased hemocystein level	6 months

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026